AstraZeneca strikes $1.5 billion AI drug discovery deal with insitro for liver and heart diseases

AstraZeneca insitro Partnership Targets Complex Diseases

AstraZeneca has entered a multi-year drug discovery collaboration and licensing agreement with AI biotech company insitro to identify treatments for liver and heart diseases.1

1

The AstraZeneca insitro partnership focuses on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, which affect the heart muscle.2

2

Both conditions represent complex, heterogeneous diseases with significant unmet medical needs, as researchers have historically struggled to pinpoint their root biological drivers.3

3

Financial Terms of the Drug Discovery Deal

Under the agreement announced Thursday, insitro will receive an upfront payment of $40 million.1

1

The AI biotech company is eligible for up to approximately $1.46 billion in milestone payments tied to development and commercial achievements.2

2

The drug discovery deal also includes potential single-digit royalties on global commercial sales of any resulting therapies.4

4

Together, these payments put the total potential value at approximately $1.5 billion, making this one of the more substantial AI drug discovery partnerships in the pharmaceutical sector.1

1

Virtual Human AI Platform Drives Drug Targets Identification

Insitro will deploy its Virtual Human AI platform to identify causal disease biology in MASH and cardiomyopathies.5

5

The platform combines laboratory-grown cell models with machine learning to help researchers study disease processes and pinpoint promising drug targets.3

3

Insitro will advance targets nominated by AstraZeneca from early discovery through to development-candidate stage.1

1

Daphne Koller, founder and CEO of insitro, explained that the vast majority of AI drug-discovery companies focus on what happens after a target has been identified, whereas insitro concentrates on the earlier stage of understanding disease biology.2

2

AstraZeneca AI Collaboration Addresses Target Selection Challenges

Sharon Barr, AstraZeneca's executive vice president and head of BioPharmaceuticals R&D, emphasized that selecting the right target remains one of the most critical decisions in research and development.1

1

"By the time we read about a new pathway or target in major scientific journals, it is no longer novel. It's in the public domain and we're already a few steps too late," Barr told Reuters.3

3

The AstraZeneca AI collaboration aims to identify unique connections early and test them in cellular systems to stay ahead.3

3

Barr added that pairing AI tools with experienced scientists allows the company to test fewer molecules in the lab and reduce guesswork.3

3

Clinical Development and Commercialization Strategy

AstraZeneca will hold exclusive worldwide rights to develop and commercialize selected programs identified through the collaboration.4

4

The pharmaceutical company will lead all clinical development, regulatory submissions, and commercialization efforts for any resulting medicines.2

2

This arrangement combines insitro's biological precision with AstraZeneca's pharmaceutical expertise and scale.1

1

The agreement supports AstraZeneca's broader strategy to expand its cardiometabolic pipeline by developing treatments that address underlying causes of diseases affecting the heart, kidneys, liver, and pancreas.4

4

Timeline Expectations for MASH and Cardiomyopathies Programs

Koller indicated that insitro has made considerable progress on the MASH side and anticipates identifying targets on a relatively near-term timeline.2

2

The cardiovascular program addressing cardiomyopathies is expected to require more time given the complexity of heart muscle diseases.2

2

This partnership comes as AstraZeneca faces setbacks in both disease areas—its drug Wainua failed to demonstrate benefit in a heart muscle disease trial earlier this year, and the drugmaker discontinued development of a mid-stage MASH candidate last year.1

1

Insitro Expands Pharmaceutical Partnerships

The AstraZeneca deal adds to insitro's growing portfolio of pharmaceutical collaborations.5

5

Insitro has existing partnerships with Bristol Myers Squibb, recently expanded to advance a broader portfolio of targets for amyotrophic lateral sclerosis.3

3

The company also collaborates with Eli Lilly to build AI models that predict pharmacological properties of small molecules in living organisms.3

3

Additionally, insitro maintains a partnership with Gilead.1

1

These collaborations highlight the pharmaceutical industry's growing interest in AI-assisted research for addressing unmet medical needs and accelerating the path from drug targets identification to potential therapies.